UK markets closed

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
285.00+5.60 (+2.00%)
At close: 05:29PM CEST
Full screen
Previous close279.40
Bid284.80 x 0
Ask285.40 x 0
Day's range278.00 - 285.40
52-week range189.03 - 302.00
Avg. volume365,629
Market cap96.862B
Beta (5Y monthly)0.23
PE ratio (TTM)45.17
EPS (TTM)6.31
Earnings date16 Jul 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est344.30
  • PR Newswire

    Invitation: Sobi's Q2 2024 report

    Sobi plans to publish its report for the second quarter of 2024 on 16 July 2024 at 08:00 CEST.

  • PR Newswire

    Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout

    Sobi® today announced the initiation of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SEL-212. The submission is based on the results of the DISSOLVE I and II pivotal studies. SEL-212 is an innovative biologic therapy in development for the treatment of chronic refractory gout, a debilitating condition characterised by the persistent and painful buildup of urate crystals in the joints.

  • PR Newswire

    European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A

    Sobi® today announced the European Commission has granted Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity. Children, adolescents, and adults can experience non-haemophilia factor VIII activity levels (above 40%) for a significant part of the week with once-weekly prophylaxis, reaching trough level